Hereditary Angioedema: European Commission approves paediatric extension for berotralstat: the first oral prophylactic treatment available in Europe for children aged 2 to less than 12 years

Berotralstat, marketed by BioCryst Ireland, a Neopharmed Gentili company, is already approved in the EU and Italy for adults and adolescents aged 12 years and older


Milan, 31 August 2026 – In Europe, children with hereditary angioedema (HAE) will now have access to an oral prophylactic treatment from the age of two. The European Commission has approved an extension of the indication for berotralstat for the routine prophylaxis of recurrent attacks of HAE in patients aged 2 to less than 12.

The therapy, marketed by BioCryst Ireland, a Neopharmed Gentili company, is already approved in the European Union and Italy for adults and adolescents aged 12 years and older.

The European Commission’s decision, which follows the positive opinion of the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), is based on results from the APeX-P clinical trial. The study demonstrated that berotralstat is generally well tolerated and capable of significantly and sustainably reducing the number of monthly attacks in paediatric patients up to 48 weeks.

Hereditary angioedema is a rare genetic disease caused by a deficiency or dysfunction of C1 inhibitor, affecting approximately one in every 50,000 people. It is characterised by unpredictable and painful episodes of swelling (edema) involving the extremities, face, abdomen and larynx. Around 50% of patients experience their first attack before the age of 10, while most develop symptoms before the age of 18.

In children the disease causes more than pain and functional limitations during attacks. The unpredictable nature of HAE episodes can affect school attendance, daily activities, sports participation and social life, with a significant impact on the entire family. Having access to a preventive treatment from the age of two allows earlier intervention, helping to prevent attacks and reduce their impact during a crucial stage of childhood development.

With the new indication, younger patients will have access to an oral prophylactic treatment available in a new granule formulation specifically designed to meet the needs of this paediatric population.

“For families across Europe, this new treatment option represents a meaningful shift for the HAE community. Children and young people living with HAE have long faced a significant unmet need, with very limited treatment options available”, said Maria Kortekaas, President of HAE Netherlands and member of the European patient advocacy group (RIPAG) of ERN-RITA, the European Reference Network for rare immunological disorders. “Having an additional treatment option offers real choice, helping families and clinicians find the approach that best fits each child’s individual needs. This allows children to focus more on being children and not to plan everyday moments around the fear of their next attack”.

This approval further strengthens Neopharmed Gentili’s commitment to rare diseases, helping expand treatment options for people living with hereditary angioedema at different stages of life.

“We are proud to make available the first oral therapy for the prophylaxis of hereditary angioedema in children aged 2 to less than 12. This is an important milestone that expands treatment options for younger patients and offers families a new perspective in managing the disease”, said Alessandro Del Bono, CEO of Neopharmed Gentili. “We hope this new therapeutic option will be accompanied by greater disease awareness, earlier diagnosis and timely access to the most appropriate treatments. This is essential to ensuring that innovation delivers meaningful benefits for patients and their families”.